Written by:
A single biomarker helped reshape how we think about cancer. Now, new science is taking it further.
Some scientific discoveries do more than deepen our understanding of disease — they change how cancer is identified, classified and treated. HER2 is one of the clearest examples in modern oncology.
First identified as a biological signal linked to more aggressive tumours, HER2 has become one of the most important biomarkers in cancer care, helping guide treatment decisions for patients around the world and shaping the broader model of precision medicine.1
Today, that story continues to evolve. Building on decades of research, scientists are uncovering a more nuanced picture of HER2 biology, revealing new insights into its role across different cancer types and how HER2 behaves within tumours.
What is HER2 and why does it matter in cancer?
HER2 (human epidermal growth factor receptor 2) is a protein found on the surface of cells. Under normal circumstances, it helps regulate cell growth and survival. But when there are extra copies of the HER2 gene, which can lead to overexpression of the HER2 protein, or when the gene acquires certain mutations, HER2 can contribute to tumour growth. HER2 is therefore an important cancer biomarker: a biological characteristic that can provide information about a tumour. Testing for HER2 can offer important insights into the biology of a person’s cancer.1,2
HER2 status is typically assessed in tumour tissue collected through biopsy, often using established testing methods such as immunohistochemistry (IHC) and in situ hybridisation (ISH).1 For years, high levels of HER2 expression were recognised as a marker of poor prognosis, with elevated HER2 commonly associated with more aggressive disease behaviour, including faster growth, earlier recurrence and a greater likelihood of spreading.1
With the development of therapies specifically designed to target HER2, researchers showed that HER2 could do more than signal prognosis; it could become an important tool to help clinicians determine targeted treatment approaches. In that shift, HER2 became one of oncology’s foundational biomarkers and one of the earliest examples of biomarker-led cancer care in practice.
How has HER2 transformed cancer care?
The HER2 story is closely linked to breast cancer, where its clinical significance first came into sharp focus. Approximately 15–20% of breast cancers overexpress HER2, and for decades these tumours were among the most difficult to treat.3,4
The development of the first HER2-directed therapies in the late 1990s marked a turning point. For the first time, treatment could be designed around a specific biological feature of a patient's tumour, rather than based only on where the cancer started in the body.4
The impact was significant. Outcomes for patients with HER2-positive breast cancer improved, and what had once been one of the most challenging breast cancer subtypes has become increasingly treatable.1,3
That success did more than help individual patients. It helped validate the broader concept of biomarker-directed therapy and set the stage for precision oncology as it is practised today. HER2 testing became standard in breast cancer, turning knowledge of HER2 biology into information that could help guide care and establishing a framework of “test, identify, target” that continues to shape cancer care across many settings.4
HER2 helped establish an entirely new model in oncology: identifying a tumour biomarker not to simply label a disease, but to help guide how it could be treated. That is a big part of why it remains such a foundational biomarker today.
How has our understanding of HER2 expanded beyond breast cancer?
Although HER2 first became widely recognised through breast cancer, researchers had long observed HER2 expression and alterations in other cancers as well. Translating those observations into meaningful treatment approaches, however, required time — along with advances in biological understanding, biomarker testing and therapeutic innovation.1
That progress is continuing the evolution of the HER2 story. Building on earlier advances in breast cancer, followed by gastric and lung cancer, research has continued to explore the role of HER2 biology in other tumour types, including biliary tract cancer and other solid tumours.5,6
The expanding relevance of HER2 across multiple tumour types reflects a broader transformation in oncology: looking beyond where a tumour starts, but also at biomarkers and other molecular and biological characteristics that may help guide treatment decisions.
As research continues to expand our understanding of HER2 across cancers, biomarker testing remains essential for identifying where that biology may be most clinically relevant.
HER2 is a powerful example of how oncology has evolved. We are no longer looking only at where a cancer begins — we are also looking at the molecular and biological characteristics influencing how the cancer cells behave, and that can change how we think about treatment.
Why is HER2 increasingly understood as a spectrum?
Another important development in the HER2 story is the growing recognition of HER2 as a spectrum of expression levels.
For many years, HER2 expression was often viewed through relatively binary classifications, with tumours generally grouped according to whether they met a specific threshold of HER2 expression. Those with high levels of HER2 expression were considered HER2 positive, while all others were classified as HER2 negative. Rather than existing as distinct categories alone, HER2 is now increasingly understood as a spectrum.4
This evolving understanding has broadened scientific interest in HER2 biology beyond tumours traditionally classified as HER2 positive, leading researchers to explore HER2 as a potential target across a wider range of tumour characteristics than was previously recognised.4
We have known for some time that HER2 can be expressed at different levels and across different tumours. What is changing now is the detail with which we can characterise and understand HER2 biology. These insights are revealing the potential relevance of HER2 across a broader range of tumours than previously recognised, while making accurate testing and interpretation more important than ever.
How is HER2 testing evolving?
The growing recognition of HER2 as a spectrum has also increased the need for more accurate and precise testing.
Established testing methods such as immunohistochemistry (IHC) and in situ hybridisation (ISH) continue to play an important role in assessing HER2. More recently, advances in genetic and molecular diagnostics have expanded the ability to identify different types of HER2 alterations.1 AI-assisted tools are also being explored to help support more consistent test interpretation and standardisation, helping to spot patterns and ensure tumours are not incorrectly identified as lacking any HER2 expression.1
Researchers have also learned that a single test result may not always tell the whole story, since HER2 expression can change over the course of a patient's cancer journey. Understanding that variability is helping scientists gain a more complete picture of tumour biology and highlighting the importance of continued advances in HER2 assessment and interpretation.3,4
What comes next for HER2 research?
HER2 remains an important area of scientific focus. Through ongoing research and collaboration, we are continuing to deepen understanding of HER2 and its clinical relevance across cancers.
The next chapter will be defined by possibilities — and continued precision. Researchers are working towards a future where tumour biology can be understood in greater detail than ever before. From more standardised biomarker assessment to AI-enabled tools that support greater specificity and consistency, advances in science are helping build a more complete picture of HER2 and other clinical characteristics. Those insights could help support a more personalised approach to cancer care than ever before.
This is an important moment in the HER2 story because the science is advancing on multiple fronts at once — challenging historic binary classifications, expanding across more tumour types, and broadening our understanding of where and how HER2 may be clinically relevant.
As the HER2 science continues to evolve, so does the opportunity to apply those insights in ways that can benefit patients. Each new discovery has the potential to refine how cancers are understood, characterised and treated. And with every question answered, new possibilities emerge.
Because what science can do is never finished.

